- Non-profit offer Anne Vojcaicki, Kofaunder and former General Manager 23Andme, agreed to buy a Genetic Testing Company for $ 305 million. Vojcicki’s return will probably cause lawsuits. The Non-Profit Institute for TTMA research, says it will adhere to the privacy policy of 23AndME.
A quick and sudden decline and attempt to rebirth the genetic testing of 23Andme took the final turn. Non-profit leading Anne Vojcicki, co-founder and former CEO of the company is reached an agreement To buy a company, with an offer of $ 305 million.
The agreement, announced late Friday, will see Vojcicki take control of basically all assets of the company.
He appeared long Vojcicki She wouldn’t regain control of the company she went in March. Biotech Company Biotech Biotech Regeneron Pharmaceuticals It was set to buy 23Andme for $ 256 million, but in the final round of the offer, Vojcicki TTMA research institute has come out of the top.
Sales of 23Andme, which used to be worth $ 6 billion, has led to the waves of nave about what would take place with genetic customer data It was held. Approximately 15% of their customers, about 1.9 million peopleThey asked for their data to be deleted from the company’s server, because 23. Marta filed for bankruptcy. The sale of the company also attracted the interest of the home supervision committee, which was concerned about where the data could be completed.
TTMA says that “privacy policies of privacy policy and applicable law” and bring “binding obligations” to create additional protection and protective measures privacy. They will include an Advisory Committee for Privacy Privacy.
Troubles 23Andme came after the HAKA company in 2023. year, which launched several concerns about the company. For example, one on a network post that offered sales data has boasted to have a huge database of Ashkenazi Jews, including people whose ties with that porcman are less than 1%.
Vojcicki, while still the executive, oversee three rounds of dismissal and suggested a plan to convert company from only supplier on supplier and in a health company that develops medication and sells health subscription reports.
He first offered Vojcicki to buy a company in mid 2024. years. The Committee for 23. January rejected his offer to attract the company private, later he stopped massively.
Purchase of 23Andme by the group leading Vojcicki will probably use lawsuits. Earlier this year, an independent investor in 23Andme talk to Happiness Expressed disbelief to keep Vojcicki, who was responsible for providing an estimate of 23Andme to turn, could turn and buy a company at a low price. “I can’t understand why there are no other offers,” investor, who asked her privacy was protected Happiness.
This story is originally presented Fortune.com
